The origins of the Vaccine Research Center date back to 1996 following discussions between President Bill Clinton and NIAID Director Dr. Anthony Fauci regarding research addressing HIV/AIDS. Recognizing the potential impact a vaccine could make in decreasing the global public health burden of HIV, President Clinton in 1997 announced a plan to establish an HIV vaccine research center on the NIH campus.[4] The dedication ceremony for the VRC took place in 1999 with President Clinton delivering the opening remarks.[5]
Named in honor of immunization advocates former Governor of ArkansasDale Bumpers and his wife Betty Flanagan Bumpers, the Vaccine Research Center opened its doors as Building 40 on the NIH campus in 2000.[6] The founding investigators leading the new center came from a range of scientific disciplines including virology, immunology, structural biology, bioengineering, manufacturing, clinical research and regulatory science. While HIV vaccine research and development remains a core focus, the scope of activities has expanded to include advancing scientific understanding and developing biologics for a broad array of infectious pathogens.
Paramyxoviruses (Parainfluenza Virus and Human Metapneumovirus)
Respiratory Syncytial Virus
Tuberculosis
Zika Virus
Projects
HIV
In July 2010, a collaboration between the National Institute of Allergy and Infectious Diseases and officials at the Vaccine Research Center found that two human HIV antibodies, named VRC01 and VRC03, could potentially be used against a wide range of types and mutations of HIV in the design of a preventive HIV vaccine for human use, as well as in the formation of better antiretroviral therapy drug cocktails. The discovery, a potentially landmark one in the drive to find a vaccine for AIDS should it be validated and further improved.
The National Institute of Allergy and Infectious Diseases is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.
Rocky Mountain Laboratories (RML) is part of the NIH Intramural Research Program and is located in Hamilton, Montana. Operated by the National Institute of Allergy and Infectious Diseases, RML conducts research on maximum containment pathogens such as Ebola as well as research on prions and intracellular pathogens such as Coxiella burnetii and Francisella tularensis. RML operates one of the few Biosafety level 4 laboratories in the United States, as well as Biosafety level 3 and ABSL3/4 laboratories.
Barton Ford Haynes is an American physician and immunologist internationally recognized for work in T-cell immunology, retrovirology, and HIV vaccine development. Haynes is a Frederic M. Hanes Professor of Medicine and Immunology at Duke University Medical Center. He is the director of the Duke Human Vaccine Institute and the Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID), which was funded by the National Institute of Allergy and Infectious Diseases (NIAID) in 2012. In addition, Haynes directs the B-cell Lineage Envelope Design Study, the Centralized Envelope Phase I Study, and the Role of IgA in HIV-1 Protection Study as part of the Collaboration for AIDS Vaccine Discovery (CAVD), which was funded by the Bill and Melinda Gates Foundation in 2006.
Bernard Moss is a virologist at the National Institute of Allergy and Infectious Diseases, part of the United States National Institutes of Health. He is the Chief of the NIAID Laboratory of Viral Diseases and of the NIAID Genetic Engineering Section. He is known for his work on poxviruses.
Julie E. Ledgerwood is an American allergist and immunologist, who is the chief medical officer and chief of the Clinical Trials Program at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health in Bethesda, Maryland. She is a Doctor of Osteopathic Medicine.
Gary J. Nabel is an American virologist and immunologist who is President and chief executive officer of ModeX Therapeutics in Natick, Massachusetts. He was the founding director of Vaccine Research Center at the National Institute of Allergy and Infectious Diseases.
A Zika virus vaccine is designed to prevent the symptoms and complications of Zika virus infection in humans. As Zika virus infection of pregnant women may result in congenital defects in the newborn, the vaccine will attempt to protect against congenital Zika syndrome during the current or any future outbreak. As of April 2019, no vaccines have been approved for clinical use, however a number of vaccines are currently in clinical trials. The goal of a Zika virus vaccine is to produce specific antibodies against the Zika virus to prevent infection and severe disease. The challenges in developing a safe and effective vaccine include limiting side effects such as Guillain-Barré syndrome, a potential consequence of Zika virus infection. Additionally, as dengue virus is closely related to Zika virus, the vaccine needs to minimize the possibility of antibody-dependent enhancement of dengue virus infection.
Ansuvimab, sold under the brand name Ebanga, is a monoclonal antibody medication for the treatment of Zaire ebolavirus (Ebolavirus) infection.
Brian R. Murphy is an American virologist and former co-chief of the Laboratory of Infectious Diseases at the National Institute of Allergy and Infectious Disease.
Emmie de Wit is a Dutch-American virologist. She is chief of the molecular pathogenesis unit at the Rocky Mountain Laboratories. Her research combines pathogenesis studies with detailed molecular analyses to identify molecular determinants of severe respiratory tract disease within the virus and the host.
Andrea Marzi is a German-American virologist. She is chief of the immunobiology and molecular virology unit at the Rocky Mountain Laboratories. Marzi investigates the pathogenesis of filoviruses and vaccine development. She received the Loeffler-Frosch medal in recognition of her research.
Kizzmekia "Kizzy" Shanta Corbett is an American viral immunologist. She is an Assistant Professor of Immunology and Infectious Diseases at Harvard T.H. Chan School of Public Health and the Shutzer Assistant Professor at the Harvard Radcliffe Institute since June 2021.
Nancy Jean Sullivan is an American cell biologist researching filovirus immunology and vaccine development. She is a senior investigator and chief of the biodefense research section at the Vaccine Research Center. Her team discovered the monoclonal antibody, mAb114.
Nicole Amy Doria-Rose (born 1970) is an American biologist. She is chief of the humoral immunology core at the Vaccine Research Center. She develops and applies assays to evaluate HIV-1 specific antibody responses during natural infection and after immunization.
Kim Yarbrough Green is an American virologist. She is chief of the caliciviruses section in the laboratory of infectious diseases at the National Institute of Allergy and Infectious Diseases. She researches noroviruses in human disease, disease prevention, and control strategies.
Catharine "Katy" Mans Bosio is an American biologist. She is a senior investigator and chief of the immunity to pulmonary pathogens section at the National Institute of Allergy and Infectious Diseases.
Vanessa M. Hirsch is a Canadian-American veterinary pathologist and scientist. She is a senior investigator and chief of the nonhuman primate virology section at the National Institute of Allergy and Infectious Diseases. Hirsch researches AIDS pathogenesis, the evolution and origins of primate lentiviruses, and HIV vaccine development.
Heinz (Heinrich) Ulrich Feldmann is a German-American virologist who currently serves as the chief of the laboratory of virology at Rocky Mountain Laboratories, NIAID and heads the Disease Modelling and Transmission section. His research focuses on highly pathogenic viruses that require strict biocontainment, including those that cause viral hemorrhagic fever such as Ebola and Lassa. He has been responsible for the development of timely viral countermeasures including the rVSV-ZEBOV vaccine (Ervebro), development of vaccines and drugs against SARS-CoV-2, and epidemiology of SARS-CoV.
Mary Elizabeth Daucher is an American biologist serving as the acting chief of the vaccine production program laboratory at Vaccine Research Center of the National Institute of Allergy and Infectious Diseases.
John R. Mascola is an American physician-scientist, immunologist and infectious disease specialist. He was the director of the Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). He also served as a principal advisor to Anthony Fauci, director of NIAID, on vaccines and biomedical research affairs. Mascola is the current Chief Scientific Officer for ModeX Therapeutics.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
President George W. Bush visits the Vaccine Research Center
President Barack Obama visits the Vaccine Research Center
President Donald Trump visits the Vaccine Research Center
President Joseph Biden visits the Vaccine Research Center
